Indications
Narrow complex tachycardias: stable SVT, and stable A-fib, atrial flutter or multifocal atrial tachycardia.
Contraindications
Hypersensitivity, Wolff-Parkinson-White syndrome, Lown-Ganong-Levine syndrome, symptomatic severe hypotension (SBP less than 90 mmHg), sick sinus syndrome or second- or third-degree heart block without a pacemaker, complete heart block. For IV use also: newborns, beta blocker therapy at the same time, cardiogenic shock, ventricular tachycardia.
Adult dose
Stable SVT, or stable A-fib, atrial flutter or MAT: 0.25 mg/kg slow IV over 2 minutes. After 15 minutes, a second dose of 0.35 mg/kg IV may be given if needed.
Older than 65: max initial dose 10 mg IV and max second dose 20 mg.
Continuous infusion for A-fib or atrial flutter, right after the bolus (FDA label): start at 10 mg/hr; some patients do well on 5 mg/hr. Increase by 5 mg/hr as needed, max 15 mg/hr. Run for up to 24 hours. Rates above 15 mg/hr and infusions longer than 24 hours are not recommended.
Pediatric dose
No pediatric dose in the national guidelines. Follow local protocol.
Route
IV, IO
Special considerations
Give it with a beta blocker such as metoprolol and you raise the risk of hypotension and bradycardia.
Avoid it in pre-excited A-fib and irregular wide complex tachycardia (WPW, LGL). In those rhythms, an AV nodal blocker can cause a paradoxical rise in the ventricular rate.
A patient with CHF may not tolerate it. Amiodarone or procainamide can be used for rate control instead.
Use only one antidysrhythmic at a time. Don't stack a second one on top.
Follow your local protocols. Sources: National Model EMS Clinical Guidelines (NASEMSO, 2022): Tachycardia with a Pulse; Purpose and Notes. FDA drug labels: Diltiazem HCl Injection (Hospira). Levels from the National EMS Scope of Practice Model (2019).